(MedPage Today) — Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the phase III POLARGO trial showed…
Source link : https://www.medpagetoday.com/meetingcoverage/eha/116098
Author :
Publish date : 2025-06-16 19:39:00
Copyright for syndicated content belongs to the linked Source.
